scholarly journals Peripartum cardiomyopathy

BMJ ◽  
2019 ◽  
pp. k5287 ◽  
Author(s):  
Michael C Honigberg ◽  
Michael M Givertz

AbstractPeripartum cardiomyopathy (PPCM) is a rare, often dilated, cardiomyopathy with systolic dysfunction that presents in late pregnancy or, more commonly, the early postpartum period. Although the condition is prevalent worldwide, women with black ancestry seem to be at greatest risk, and the condition has a particularly high incidence in Nigeria and Haiti. Other risk factors include pre-eclampsia, advanced maternal age, and multiple gestation pregnancy. Although the complete pathophysiology of peripartum cardiomyopathy remains unclear, research over the past decade suggests the importance of vasculo-hormonal pathways in women with underlying susceptibility. At least some women with the condition harbor an underlying sarcomere gene mutation. More than half of affected women recover systolic function, although some are left with a chronic cardiomyopathy, and a minority requires mechanical support or cardiac transplantation (or both). Other potential complications include thromboembolism and arrhythmia. Currently, management entails standard treatments for heart failure with reduced ejection fraction, with attention to minimizing potential adverse effects on the fetus in women who are still pregnant. Bromocriptine is one potential disease specific treatment under investigation. In this review, we summarize the current literature on peripartum cardiomyopathy, as well as gaps in the understanding of this condition and future research directions.

2012 ◽  
Vol 111 (suppl_1) ◽  
Author(s):  
Zolt Arany ◽  
Ian Patten ◽  
Sarosh Rana ◽  
Sajid Shahul ◽  
Glenn Rowe ◽  
...  

Peri-partum cardiomyopathy (PPCM) is a frequently fatal disease that affects women near delivery, and occurs more frequently in women with pre-eclampsia and/or multiple gestation. The etiology of PPCM, or why it associates with pre-eclampsia, remains unknown. We show here that PPCM is associated with a systemic angiogenic imbalance, accentuated by pre-eclampsia. Mice that lack cardiac PGC-1α, a powerful regulator of angiogenesis, develop profound PPCM. Importantly, the PPCM is entirely rescued by pro-angiogenic therapies. In humans, the placenta in late gestation secretes VEGF inhibitors like soluble Flt1 (sFlt1), and this is accentuated by multiple gestation and pre-eclampsia. This anti-angiogenic environment is accompanied by sub-clinical cardiac dysfunction, the extent of which correlates with circulating levels of sFlt1. Exogenous sFlt1 alone caused diastolic dysfunction in wildtype mice, and profound systolic dysfunction in mice lacking cardiac PGC-1α. Finally, plasma samples from women with PPCM contained abnormally high levels of sFlt1. These data strongly suggest that PPCM is in large part a vascular disease, caused by excess anti-angiogenic signaling in the peri-partum period. The data also explain how late pregnancy poses a threat to cardiac homeostasis, and why pre-eclampsia and multiple gestation are important risk factors for the development of PPCM.


SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A291-A292
Author(s):  
Lily Arnett ◽  
David Kalmbach ◽  
Brian Ahmedani ◽  
Bizu Gelaye ◽  
Christopher Drake ◽  
...  

Abstract Introduction This prospective study explored associations among clinical insomnia, nocturnal cognitive hyperarousal, and nocturnal perinatal-focused rumination with suicidal ideation (SI) in perinatal women with mild-to-moderate depression. Methods From late pregnancy through early postpartum, 39 women with depression completed 17 weekly surveys assessing insomnia, depression, suicidal ideation, perceived stress, and three cognitive arousal indices. Results Women with nocturnal cognitive hyperarousal at baseline, relative to those with low nocturnal cognitive arousal, were at greater risk for developing new onset SI in late pregnancy or early postpartum (33% vs 1%). Moreover, nocturnal perinatal-focused rumination was independently associated with SI. SI-risk was highest when women reported clinical insomnia combined with nocturnal cognitive hyperarousal (OR=5.66, p=.037) or perinatal-focused rumination (OR=11.63, p=.018). Daytime perseverative thinking was not uniquely associated with SI. Conclusion Cognitive hyperarousal and perinatal-focused rumination at night are uniquely associated with SI among perinatal women with depression. Moreover, insomnia augments the suicidogenicity of nighttime cognitive activity. Future research should determine whether alleviating nocturnal cognitive arousal, pregnancy- and fetal/infant-related concerns, and insomnia with psychotherapy reduces SI for women with perinatal depression. Support (if any) This study was funded by the American Academy of Sleep Medicine (198-FP-18, PI: Kalmbach). Dr. Cheng’s effort was supported by the National Heart, Lung, and Blood Institute (K23-HL13866, PI: Cheng).


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
A C Mbakwem ◽  
J Bauersachs ◽  
C Viljoen ◽  
P Van Der Meer ◽  
M Petrie ◽  
...  

Abstract Background Cardiac disease remains an important cause of maternal morbidity and mortality globally. Peripartum cardiomyopathy (PPCM), defined as heart failure secondary to left ventricular (LV) systolic dysfunction in previously healthy women towards the end of pregnancy or up to five months following delivery, can result in cardiogenic shock due to severe LV dysfunction or arrhythmias leading to sudden cardiac death. Cardiac electrical activity and its relationship to cardiac dysfunction have not yet been interrogated in large multi-centre studies. Purpose This study aimed to identify the ECG abnormalities associated with PPCM; their relationship with echocardiographic structural and functional abnormalities and explore regional and ethnic differences in ECG features. Methods We included the first 411 patients enrolled into the EURObservational PPCM registry (EORP). Baseline demographic, clinical and echocardiographic data were collected. ECGs were analysed for rate; rhythm; QRS width, axis and morphology; and QTc interval. Results Mean age of the women (from >40 countries) was 30.7±6.4 years. More than two thirds of patients presented with NYHA class III or IV (with no regional differences). The median QRS rate was 102bpm (IQR 87–117). More than half presented with sinus tachycardia (QRS rate >100bpm), whereas atrial fibrillation was rare (2.27%). The mean QRS width was 90.1ms ±21.5, with regional differences (ESC 93.8ms ±21.7 vs. non-ESC 86.8ms ±20.8, P<0.001). Left bundle branch block (LBBB) was reported in 9.30% with no regional or ethnic differences. Left ventricular hypertrophy (LVH) was present in a quarter of the cohort, and more prevalent amongst African (59.62%) and Asian (23.17%) than Caucasians (7.63%, P<0.001). The median QTc by Bazett was 456.7ms (IQR 409–490.7) and almost half (47.11%) had prolonged QTc (>460ms). The median LVEDD was 60mm (IQR 55–65) on echocardiography. Compared with their Asian and Caucasian counterparts, African patients were more likely to have LV dilatation (LVEDD>53mm: 70.11%, 79.31% and 89.42% respectively; P=0.004). The median LV ejection fraction (LVEF) was 32.50% (IQR 25–39) with no significant regional or ethnic differences. Sinus tachycardia predicted poor systolic function (OR 1.85 [95% CI 1.20–2.85], p=0.006). LVEF <35% was associated with a significantly higher QRS rate (median rate 107 vs. 98bpm, p=0.002). Women with LVEDD ≥53mm had a longer mean QRS duration (92.0±22.4 vs. 82.4±15.4ms, p<0.001) and frequency of LBBB (11.15% vs 1.54%, p=0.016). LBBB was a predictor of LVEDD >53mm (sensitivity 11.15%; specificity 98.46%; PPV 97.14%; NPV 19.10%; OR 8.02 [95% CI 1.08–59.66], p=0.042). Conclusion Patients with PPCM commonly present with sinus tachycardia, LVH, and/or prolonged QTc interval on their ECG. Wide QRS and/or LBBB, were associated with LVEDD>53mm. Sinus tachycardia, however, was associated with LVEF<35%. Risk of arrhythmia in those with prolonged QTc remains to be ascertained. Acknowledgement/Funding Heart Failure Association of the ESC


2012 ◽  
Vol 2012 ◽  
pp. 1-6 ◽  
Author(s):  
Piercarlo Ballo ◽  
Irene Betti ◽  
Giuseppe Mangialavori ◽  
Leandro Chiodi ◽  
Gherardo Rapisardi ◽  
...  

Management of patients with peripartum cardiomyopathy (PPCM) is still a major clinical problem, as only half of them or slightly more show complete recovery of left ventricular (LV) function despite conventional evidence-based treatment for heart failure. Recent observations suggested that bromocriptine might favor recovery of LV systolic function in patients with PPCM. However, no evidence exists regarding its effect on LV diastolic dysfunction, which is commonly observed in these patients. Tissue Doppler (TD) is an echocardiographic technique that provides unique information on LV diastolic performance. We report the case of a 37-year-old white woman with heart failure (NYHA class II), moderate LV systolic dysfunction (ejection fraction 35%), and severe LV diastolic dysfunction secondary to PPCM, who showed no improvement after 2 weeks of treatment with ramipril, bisoprolol, and furosemide. At 6-week followup after addition of bromocriptine, despite persistence of LV systolic dysfunction, normalization of LV diastolic function was shown by TD, together with improvement in functional status (NYHA I). At 18-month followup, the improvement in LV diastolic function was maintained, and normalization of systolic function was observed. This paper might support the clinical utility of bromocriptine in patients with PPCM by suggesting a potential benefit on LV diastolic dysfunction.


2021 ◽  
Vol 10 (2) ◽  
pp. 203
Author(s):  
Eleni-Evangelia Koufou ◽  
Angelos Arfaras-Melainis ◽  
Sahil Rawal ◽  
Andreas P. Kalogeropoulos

In this review, we briefly outline our current knowledge on the epidemiology, outcomes, and pathophysiology of heart failure (HF) with mid-range ejection fraction (HFmrEF), and discuss in more depth the evidence on current treatment options for this group of patients. In most studies, the clinical background of patients with HFmrEF is intermediate between that of patients with HF and reduced ejection fraction (HFrEF) and patients with HF and preserved ejection fraction (HFpEF) in terms of demographics and comorbid conditions. However, the current evidence, stemming from observational studies and post hoc analyses of randomized controlled trials, suggests that patients with HFmrEF benefit from medications that target the neurohormonal axes, a pathophysiological behavior that resembles that of HFrEF. Use of β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid receptor antagonists, and sacubitril/valsartan is reasonable in patients with HFmrEF, whereas evidence is currently scarce for other therapies. In clinical practice, patients with HFmrEF are treated more like HFrEF patients, potentially because of history of systolic dysfunction that has partially recovered. Assessment of left ventricular systolic function with contemporary noninvasive modalities, e.g., echocardiographic strain imaging, is promising for the selection of patients with HFmrEF who will benefit from neurohormonal antagonists and other HFrEF-targeted therapies.


2012 ◽  
Vol 1 (1) ◽  
pp. 37-42
Author(s):  
AMB Safder ◽  
SA Mir ◽  
BM Miah ◽  
RJ Tamanna ◽  
AKM Mohibullah

A 32 year-old primigravida with gestational diabetes & subclinical hypothyroidism on replacement therapy and no previous cardiac problem, developed features of shock few hours after elective caesarian section at term, in the absence of any chest pain or palpitation. Following resuscitation she developed features of acute left ventricular failure. ECG showed nonspecific T changes, chest x-ray revealed enlarged cardiac shadow with pulmonary congestion, arterial blood gas analysis was normal with supplemental oxygen. Serial cardiac markers were normal & serum d-Dimer was negative. Echocardiogram revealed dilatation of all cardiac chambers with global hypokinesia & severe left ventricular (LV) systolic dysfunction. She was diagnosed as a case of peripartum cardiomyopathy and treated conservatively with medications. Her condition improved dramatically & she became symptom-free by the 5th post-operative day (POD) and subsequently discharged on 9th POD. Follow-up echocardiogram after 6 weeks revealed regional wall motion abnormality, normal chamber dimensions and fair LV systolic function. DOI: http://dx.doi.org/10.3329/birdem.v1i1.12387 Birdem Med J 2011; 1(1): 37-42


2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
Q Chen ◽  
J Lin ◽  
Y Kang ◽  
R Zhang ◽  
Q Zhang

Abstract Background Echocardiography (echo) has become a well-accepted noninvasive examination for patients with confirmed or suspected cardiac structural and/or functional abnormalities, by not only heart doctors but also non-heart doctors. Left ventricular ejection fraction (LVEF) as the most important parameter of cardiac systolic function must be listed on every echo report. A LVEF of <50% has been regarded as LV systolic dysfunction with reduced ejection fraction. Purpose This study aimed to test whether a warning label as “reduced LVEF” on echo report would change the attitude or practice with regard to heart failure (HF) diagnosis and treatment in non-heart doctors. Methods From January to June, 2018, the program was conducted by adding a warning label as “reduced LVEF” next to the LVEF reading on echo report if it was <50%. The patients with a reported LVEF <50% and an echo request from non-heart doctors (cardiologists or cardiac surgeons) were selected (labeled group, n=359) for analysis, and a similar group of patients from January to June, 2017 were served as controls (unlabeled group, n=367). The rates of HF diagnosis, N-terminal-pro-B-type natriuretic peptide (NT-proBNP) test, cardiologist consultation and anti-HF medical therapy at discharge were compared between the 2 groups. Results There were no major differences in baseline characteristics between the 2 groups. The labeled group received more opportunities of cardiologist consultation (53.2% vs. 44.7%, p=0.02) and referral to cardiology outpatient clinic (57.9% vs. 50.1%, p=0.04) when compared with the unlabeled group. However, the difference was mainly found in patients with a LVEF of 40–49% (n=448, 53.2% of the labeled group vs. 44.7% of the unlabeled group, p=0.02). By pooling the data from the labeled and unlabeled groups, the patients who received cardiologist consultation (n=355) had a significant improvement in HF diagnosis and management than those who did not have a chance of cardiologist consultation (n=371), in terms of higher rates of NT-proBNP test (59.6% vs. 80.8%, p<0.01) and standardized anti-HF medication (Renin-anigotensin system inhibitors: 23.7% vs. 37.2%, p<0.01; β blockers: 22.1% vs. 33.8%, p<0.01; mineralocorticoid Receptor Antagonists: 27.5% vs. 35.5%, p<0.01). Conclusions An added warning label as “reduced LVEF” on echo report beside the LVEF reading would enhance the awareness of systolic HF and the appropriate management in non-heart doctors, in particular for patients with a LVEF of 40∼49%. Acknowledgement/Funding The study was supported by a research grant from the Science and Technology Department of Sichuan Province (project number: 2017SZ0059)


1970 ◽  
Vol 24 (2) ◽  
pp. 67-70
Author(s):  
Shirin Akter Begum ◽  
SB Chowdhury ◽  
Begum Nasrin ◽  
Jannatul Ferdous ◽  
Zillur Rahman Bhuiyan

Peripartum cardiomyopathy (PPCM) is a rare but potentially lethal complication of pregnancy occurring in approximately 1in 3000 live births in the United States although some series report a much higher incidence. African-American women are particularly at risk. Diagnosis requires symptoms of heart failure in the last month of pregnancy or within five months of delivery in the absence of recognized cardiac disease prior to pregnancy as well as objective evidence of left ventricular systolic dysfunction. Obstetricians should suspect the diagnosis, particularly if the patient has risk factors. Evaluation should include an echocardiogram to assess the LV systolic function. Treatment includes ACE inhibitors or angiotensin receptor blockers, beta-blockers, and diuretics. Consideration should be given to anticoagulation. A number of causes are being investigated, including nutritional, infectious, and genetic, which, hopefully, lead to more targeted treatments. This paper provides an updated, comprehensive review of PPCM, including emerging insights into the etiology of this disorder as well as current treatment options. Bangladesh J Obstet Gynaecol, 2009; Vol. 24(2) : 67-70   DOI: http://dx.doi.org/10.3329/bjog.v24i2.8531


Sign in / Sign up

Export Citation Format

Share Document